Brian Bernick Sells 182,800 Shares of TherapeuticsMD Inc (TXMD) Stock

TherapeuticsMD Inc (NASDAQ:TXMD) Director Brian Bernick sold 182,800 shares of the firm’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $4.74, for a total value of $866,472.00. Following the completion of the sale, the director now directly owns 242,000 shares of the company’s stock, valued at $1,147,080. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Brian Bernick also recently made the following trade(s):

  • On Friday, November 9th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.88, for a total value of $892,064.00.
  • On Friday, October 19th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.56, for a total value of $1,016,368.00.
  • On Friday, October 5th, Brian Bernick sold 91,400 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.93, for a total value of $542,002.00.
  • On Friday, September 28th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.59, for a total value of $1,204,652.00.
  • On Thursday, September 13th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.30, for a total value of $1,151,640.00.

Shares of TXMD stock opened at $4.90 on Friday. TherapeuticsMD Inc has a 52-week low of $4.30 and a 52-week high of $7.66. The company has a debt-to-equity ratio of 0.55, a current ratio of 7.23 and a quick ratio of 7.15. The company has a market cap of $1.15 billion, a P/E ratio of -13.24 and a beta of 1.40.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.06. TherapeuticsMD had a negative return on equity of 102.15% and a negative net margin of 757.59%. The firm had revenue of $3.47 million during the quarter, compared to analyst estimates of $4.43 million. During the same period last year, the company earned ($0.07) EPS. TherapeuticsMD’s quarterly revenue was down 21.5% compared to the same quarter last year. Research analysts expect that TherapeuticsMD Inc will post -0.58 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Stevens Capital Management LP bought a new stake in TherapeuticsMD during the 3rd quarter valued at $101,000. B. Riley Wealth Management Inc. purchased a new position in shares of TherapeuticsMD in the 3rd quarter valued at $102,000. Fox Run Management L.L.C. purchased a new position in shares of TherapeuticsMD in the 2nd quarter valued at $121,000. Managed Account Services Inc. purchased a new position in shares of TherapeuticsMD in the 3rd quarter valued at $117,000. Finally, Twin Focus Capital Partners LLC purchased a new position in shares of TherapeuticsMD in the 2nd quarter valued at $187,000. 67.56% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently issued reports on TXMD. ValuEngine raised TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Friday, September 21st. Oppenheimer set a $14.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, September 26th. Cantor Fitzgerald set a $27.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a research note on Thursday, September 27th. BidaskClub raised TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 29th. Finally, Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Saturday, August 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $13.45.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/11/23/brian-bernick-sells-182800-shares-of-therapeuticsmd-inc-txmd-stock.html.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Further Reading: Cash Flow Analysis in Stock Selection

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply